Terms: = Leukemia AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
234 results:
1. Serum interleukin-33 and soluble suppression of tumorigenicity 2 in pediatric leukemia with febrile neutropenia.
Polat MC; Sönmez Ç; Yarali N; Özbek NY
Eur J Pediatr; 2024 May; 183(5):2155-2162. PubMed ID: 38367066
[TBL] [Abstract] [Full Text] [Related]
2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
3. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage erbb2/her2-Positive Breast Cancer.
Zagami P; Fernandez-Martinez A; Rashid NU; Hoadley KA; Spears PA; Curigliano G; Perou CM; Carey LA
JAMA Netw Open; 2023 Dec; 6(12):e2348814. PubMed ID: 38117494
[TBL] [Abstract] [Full Text] [Related]
4. Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
Lipsyc-Sharf M; Ballman KV; Campbell JD; Muss HB; Perez EA; Shulman LN; Carey LA; Partridge AH; Warner ET
JAMA Netw Open; 2023 Oct; 6(10):e2339584. PubMed ID: 37878313
[TBL] [Abstract] [Full Text] [Related]
5. [A comparative study of the effects of citrate and heparin anticoagulation on coagulation function and efficacy in children with septic shock undergoing continuous blood purification].
Zhong X; Luo S; Ren R; Lai J; Deng G; Zhu H
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Aug; 35(8):856-859. PubMed ID: 37593866
[TBL] [Abstract] [Full Text] [Related]
6. Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy.
Dong S; Matossian MD; Yousefi H; Khosla M; Collins-Burow BM; Burow ME; Alahari SK
Sci Rep; 2023 Jul; 13(1):11843. PubMed ID: 37481672
[TBL] [Abstract] [Full Text] [Related]
7. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.
Shyam Sunder S; Sharma UC; Pokharel S
Signal Transduct Target Ther; 2023 Jul; 8(1):262. PubMed ID: 37414756
[TBL] [Abstract] [Full Text] [Related]
8. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
[TBL] [Abstract] [Full Text] [Related]
9. Evaluating the Activity of neuraminidase in Bacterial Vaginosis Microflora and Imaging Sialic Acid on the Cell Membrane by Boron and Nitrogen Codoped Fluorescent Carbon Dots.
Liu X; Zhang Y; Yu W; Zhang W; Jiang J; Gu Q; Wang X; Wu Y
ACS Sens; 2023 Jul; 8(7):2556-2562. PubMed ID: 37322599
[TBL] [Abstract] [Full Text] [Related]
10. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S; Xie SM; Liu W; Gagea M; Hanker AB; Nguyen N; Singareeka Raghavendra A; Yang-Kolodji G; Chu F; Neelapu SS; Marchese A; Hanash S; Zimmermann J; Arteaga CL; Tripathy D
Breast Cancer Res; 2023 Jun; 25(1):62. PubMed ID: 37280713
[TBL] [Abstract] [Full Text] [Related]
11. Mechanism of Procyanidin B2 in the treatment of Chronic Myeloid leukemia Based on Integrating Network Pharmacology and Molecular Docking.
Li HX; Jing YX; Chai YH; Sun XH; He XX; Xue SL; Xi YM; Ma XL
Anticancer Agents Med Chem; 2023; 23(16):1838-1847. PubMed ID: 37246327
[TBL] [Abstract] [Full Text] [Related]
12. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest.
Cao W; Yao S; Li A; Chen H; Zhang E; Cao L; Zhang J; Hou Y; Dai Z; Chen J; Huang X; Yang L; Cai Z
J Zhejiang Univ Sci B; 2023 May; 24(5):442-454. PubMed ID: 37190893
[TBL] [Abstract] [Full Text] [Related]
13. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Parker BA; Shatsky RA; Schwab RB; Wallace AM; ; Wolf DM; Hirst GL; Brown-Swigart L; Esserman LJ; van 't Veer LJ; Ghia EM; Yau C; Kipps TJ
Breast Cancer Res Treat; 2023 Jun; 199(2):281-291. PubMed ID: 37029329
[TBL] [Abstract] [Full Text] [Related]
14. [Efficacy and safety of dexcitabine combined with HAAG regimen in the treatment of recurrent acute myeloid leukemia].
Wu XF; Li CC; Li TT; Sun L; Lu J; Ran XH
Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(13):981-985. PubMed ID: 36990713
[No Abstract] [Full Text] [Related]
15. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
[TBL] [Abstract] [Full Text] [Related]
16. A CD19-Anti-erbb2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate erbb2
Hombach AA; Ambrose C; Lobb R; Rennert P; Abken H
Cells; 2023 Jan; 12(2):. PubMed ID: 36672182
[TBL] [Abstract] [Full Text] [Related]
17. Acridine as an Anti-Tumour Agent: A Critical Review.
Varakumar P; Rajagopal K; Aparna B; Raman K; Byran G; Gonçalves Lima CM; Rashid S; Nafady MH; Emran TB; Wybraniec S
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615391
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage erbb2/her2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Fernandez-Martinez A; Pascual T; Singh B; Nuciforo P; Rashid NU; Ballman KV; Campbell JD; Hoadley KA; Spears PA; Pare L; Brasó-Maristany F; Chic N; Krop I; Partridge A; Cortés J; Llombart-Cussac A; Prat A; Perou CM; Carey LA
JAMA Oncol; 2023 Apr; 9(4):490-499. PubMed ID: 36602784
[TBL] [Abstract] [Full Text] [Related]
19. Expression of TRX1 optimizes the antitumor functions of human CAR T cells and confers resistance to a pro-oxidative tumor microenvironment.
Balta E; Janzen N; Kirchgessner H; Toufaki V; Orlik C; Liang J; Lairikyengbam D; Abken H; Niesler B; Müller-Decker K; Ruppert T; Samstag Y
Front Immunol; 2022; 13():1063313. PubMed ID: 36591284
[TBL] [Abstract] [Full Text] [Related]
20. Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.
Karacin C; Bilgetekin I; Basal FB; Oksuzoglu OB
J Coll Physicians Surg Pak; 2022 Nov; 32(11):1501-1502. PubMed ID: 36377026
[TBL] [Abstract] [Full Text] [Related]
[Next]
